The Effect of Parathyroid Hormone on Cisplatin Nephrotoxicity

  • Giovambattista Capasso
  • Dario R. Giordano
  • Natale G. De Santo
  • Shaul G. Massry
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 252)


The clinical use of cisplatin as an antineoplastic agent is limited by its nephrotoxicity that, in many cases, includes acute tubular necrosis and renal wasting of various electrolytes (1–4). Several studies have been performed to account for the various disorders of renal function induced by cisplatin. The decrease in GFR, for example, has been found to be related to a reduction in renal blood flow and to a lowered effective filtration pressure (5). The reported concentrating defect and the observed impaired sodium reabsorption have been associated to a defect in papillary hypertonicity found in cisplatin treated rats (6), while the potassium wasting effect is in part due to a negative potential difference induced by cisplatin in late distal segments (6). Finally the pathogenesis of cisplatin induced hypomagnesemia has been attributed to pathological changes confined to the straight portion (S3 segment) of superficial nephrons (7). On the other hand many therapeutic strategies have been tested to reduce its nephrotoxic action: the fall in GFR, for example, can be modified by hydration, mannitol diuresis (8) and by the administration of atrial natriuretic peptide (9); moreover compounds that provide SH groups have been reported to reduce the cisplatin associated renal injury (10).


Acute Renal Failure Atrial Natriuretic Peptide Plasma Calcium Level Renal Cortical Slice Superficial Nephron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Einhorn LH, Williams SD: The role of cisplatinum in solid tumor therapy. New Engl J Med 300:289–291, 1978.CrossRefGoogle Scholar
  2. 2.
    Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 65:307–314, 1978.PubMedCrossRefGoogle Scholar
  3. 3.
    Chopra S, Kaufman J, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flammenbaum W, Trump BF: Cis-diamminedichloroplatinum induced acute renal failure in the rat. Kidney Int 21:54–64, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Gordon JA, Peterson LN, Anderson RJ: Water fluid metabolism after cisplatin in the rat. Am J Physiol 243:F36-F43, 1982.PubMedGoogle Scholar
  5. 5.
    Winston JA, Safirstein R: Reduced renal blood flow in cisplatin induced acute renal failure in the rat. Am J Physiol 249:F490-F496, 1985.PubMedGoogle Scholar
  6. 6.
    Allen GG, Barrat LJ: Effect of cisplatin on the transepithelial potential difference of rat distal tubule. Kidney Int 27:842–847, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Mavichak V, Wong NLM, Quamme GA, Magil AB, Sutton RAL, Dirks JH: Studies on the pathogenesis of cis-platin induced hypomagnesemia in rats. Kidney Int 28:914–921, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC: High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19–24, 1984.PubMedGoogle Scholar
  9. 9.
    Capasso G, Anastasio P, Giordano DR, Albarano L, De Santo NG: Beneficial effects of atrial natriuretic factor on cisplatin induced acute renal failure in the rat. Am J Nephrol 7:228–234, 1987.PubMedCrossRefGoogle Scholar
  10. 10.
    Borch R, Pleasants ME: Inhibition od cis-platinum nephrotoxicity by diethyl-dithiocarbamate rescue in a rat model. Proc Natl Acad Sci USA 76:6611–6614, 1979.PubMedCrossRefGoogle Scholar
  11. 11.
    Burke TJ, Arnold PE, Gordon JA, Bulger RE, Dobyan DC, Schrier RW: Protective effect of intrarenal calcium membrane blockers before and after renal ischemia. Functional,morphological and mitochondrial studies. J Clin Invest 74:1830–1841, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    Bennet WM, Pulliam JP, Porter GA, Houghton DC: Modification of experimental gentamicin nephrotoxicity by selective parathyroidectomy. Am J Physiol:F832-F835, 1985.Google Scholar
  13. 13.
    Nagata N, Rasmussen H: Parathyroid hormone, 3’, 5’ - AMP, Ca and renal gluconeogenesis. Proc Natl Acad Sci USA 65:368–374, 1970.PubMedCrossRefGoogle Scholar
  14. 14.
    Schanne FAX, Kane AB, Young EE, Färber JL: Calcium dependence of toxic cell death: a final common pathway. Science 206:700–702, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Färber JL: The role of calcium in cell death. Life Sci 29:1289–1295,1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Offerman JJG, Meijer S, Sleijfer DTh, Mulder NH, Donker AJM, Schraffordt Koops H, Van Der Hern GK: The influence of verapamil on renal function in patients treated with cisplatin. Clinical Nephrology 24:249–255, 1985.PubMedGoogle Scholar
  17. 17.
    Cheung JY, Bonventre JV, Malis CD, Leaf A: Calcium and ischemic injury. N Engl J Med 314:1670–1676, 1986.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Giovambattista Capasso
    • 1
  • Dario R. Giordano
    • 1
  • Natale G. De Santo
    • 1
  • Shaul G. Massry
    • 1
  1. 1.Chair of Pediatric Nephrology, Department of Pediatrics, Ist Faculty of MedicineUniversity of NaplesItaly

Personalised recommendations